细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响

doi:10.12092/j.issn.1009-2501.2018.02.008

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (2): 159-164.doi: 10.12092/j.issn.1009-2501.2018.02.008

细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响

肖鹏¹，梅家转¹，白桦¹，栗敏¹，刘桂举¹，李瑞君¹，沈杰²

¹郑州人民医院肿瘤科，郑州 450000，河南； ²皖南医学院弋矶山医院临床药学部，芜湖 241001，安徽

收稿日期:2017-09-20 修回日期:2017-11-04 出版日期:2018-02-26 发布日期:2018-03-02
通讯作者: 梅家转，男，博士，主任医师，研究方向：恶性肿瘤内科治疗及生物治疗。 Tel:13526526109 E-mail: mjzhuan@163.com
作者简介:肖鹏，男，硕士，主治医师，研究方向：恶性肿瘤内科治疗。 Tel: 13783593134 E-mail: zzrmyyxiaopeng@sina.com

Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine

XIAO Peng¹, MEI Jiazhuan¹, BAI Hua¹, LI Min ¹, LIU Guiju¹, LI Ruijun¹, SHEN Jie²

¹Department of Oncology, People's Hospital of Zhengzhou, Zhengzhou 450000, Henan, China; ²Department of Clinical Pharmacy, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2017-09-20 Revised:2017-11-04 Online:2018-02-26 Published:2018-03-02

摘要/Abstract

摘要：

目的: 探讨细胞色素450（CYP450）酶的基因变异是否是奥沙利铂联合卡培他滨的方案在结直肠癌患者中的治疗结果差异的影响因素。方法: 研究入组69例接受奥沙利铂联合卡培他滨方案治疗的结直肠癌（colorectal cancer,CRC）患者，同时对细胞色素450（CYP450）基因上最小等位基因频率（MAF）≥10%的79个多态性位点进行基因分型。对这些单核苷酸多态性（SNP）位点和治疗反应率以及预后的相关性进行分析。结果: 发现仅CYP1A1的rs1048943（Ile462Val）和无进展生存期（PFS）显著相关（P=0.0003），其他位点和治疗反应率以及总生存期（OS）无明显相关性。纳入Cox风险比例模型当中校正之后，发现该位点是影响PFS独立的预后指标（P=0.004）。结论: CYP1A1上的多态性位点rs1048943（Ile462Val）对接受奥沙利铂联合卡培他滨方案治疗的CRC患者来说可能是一个可以预测预后的独立指标。

关键词: 结直肠癌, 细胞色素P450, 多态性

Abstract:

AIM: To investigate whether gene variants of cytochrome P450 (CYP450) affected clinical outcomes of oxaliplatin plus capecitabine in colorectal cancer (CRC). METHODS: Sixty-nine CRC patients who were treated with oxaliplatin plus capecitabine were included in this study. And 79 SNPs in CYP450, whose minor allele frequency (MAF) were >10% were genotyped. Association between the SNP and clinical outcomes were analyzed. RESULTS: Only one SNP, CYP1A1 rs1048943 was significantly associated with PFS (P=0.000 3). Multivariate analysis confirmed its prognostic significance for PFS (P=0.004). CONCLUSION: CYP1A1 rs1048943 polymorphism is probably a potential prognostic marker for survival outcome treated with oxaliplatin plus capecitabine chemotherapy in CRC patients.

Key words: colorectal cancer, CYP450, polymorphism

中图分类号:

R735.3+5

肖鹏，梅家转，白桦，栗敏，刘桂举，李瑞君，沈杰. 细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 159-164.

XIAO Peng, MEI Jiazhuan, BAI Hua, LI Min, LIU Guiju, LI Ruijun, SHEN Jie. Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 159-164.

参考文献

［1］Loree JM, Kopetz S. Recent developments in the treatment of metastatic colorectal cancer［J］. Ther Adv Med Oncol,2017,9(8):551-564.
［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016,66(2):115-132.
［3］Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes［J］. Eur J Cancer,2017,84:69-80.
［4］周密，邱峰，张渊，等. 美洛昔康对人结肠癌细胞增殖、迁移和PTEN基因表达的影响［J］. 中国药理学通报,2015,31(12):1704-1709.
［5］Aparicio T, Francois E, Cristol-Dalstein L, et al. PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial［J］. Dig Liver Dis,2016,48(2):206-207.
［6］Lonardi S, Sobrero A, Rosati G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial［J］. Ann Oncol, 2017，27(11):2074-2081.
［7］Ingelman-Sundberg M, Sim SC, Gomez A, et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects［J］. Pharmacol Ther, 2007, 116(3):496-526.
［8］Watson RG, Mcleod HL. Pharmacogenomic contribution to drug response ［J］. Cancer J, 2011,17(2):80-88.
［9］Zhang DY, Yuan XQ, Yan H, et al. Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients ［J］. Pharmacogenomics, 2016, 17(14):1519-1531.
［10］Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future［J］. Trends Pharmacol Sci, 2004, 25(4):193-200.
［11］Oztas E, Ozhan G, Daly AK. The effect of the CYP1A1*2A allele on colorectal cancer susceptibility in a British population［J］. Genet Test Mol Biomarkers, 2016, 20(8):475-477.
［12］Sun H, Wang C, Hao M, et al. CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer［J］. Hum Pathol, 2016, 50:101-108.
［13］Wang H, Ren L, He Y, et al. Association between cytochrome P4502C9 gene polymorphisms and colorectal cancer susceptibility: evidence from 16 case-control studies ［J］. Tumor Biol, 2014, 35(5):4317-4322.
［14］Ribrag V. Towards common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST ［J］ ? Ann Oncol, 2017, 28 (7), 1409-1411.
［15］Trumpi K, Ubink I, Trinh A, et al. Neoadjuvant chemotherapy affects molecular classification of colorectal tumors［J］. Oncogenesis,2017,6(7):e357.
［16］Dong N, Meng F, Wu Y, et al. Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer［J］. Tumor Biol,2015,36(10):7691-7698.
［17］Yeh CC, Lai CY, Chang SN, et al. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy［J］. Int J Clin Oncol,2017,22(3):484-493.
［18］Patricia RC, Janeth RC, Alonso LY, et al. Thymidylate synthase polymorphism in Mexican patients with colon cancer treated with 5-fluorouracil［J］. J Buon,2016,21(4):935-940.
［19］Cosma G, Crofts F, Taioli E, et al. Relationship between genotype and function of the human CYP1A1 gene［J］. J Toxicol Environ Health,1993,40(2/3):309-316.
［20］Kaida Y, Inui N, Suda T, et al. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer［J］. Clin Pharmacol Ther, 2008, 83(4): 589-594.
［21］Zeng Z, Liu Y, Liu Z, et al. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis［J］. Cancer Chemother Pharmacol, 2013, 72(2): 287-303.
［22］Chen Z, Li Z, Niu X, et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies［J］. Mutagenesis,2011,26(3):437-446.
［23］Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis［J］. Breast Cancer Res Treat, 2010,122(2):459-469.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[4]	周晶, 周琛, 廖珂, 邱爱林, 董巍檑, 郭紫芬. 孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 400-406.
[5]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[6]	卫真真, 隋华, 姜宇朗, 孙明瑜, 闫化茹, 王子元. 左金丸联合西妥昔单抗诱导KRAS突变肠癌细胞铁死亡作用研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 130-137.
[7]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[8]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[9]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[10]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[11]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[12]	周广琛, 刘怡希, 郑云. 结直肠癌和microRNA：研究进展[J]. 中国临床药理学与治疗学, 2022, 27(5): 575-587.
[13]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[14]	李岩岩, 方骁杰, 尹鑫, 孙曦, 饶春晖. circZNF124通过靶向miR-4262调控结直肠癌SW620细胞增殖、迁移及侵袭的机制研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1231-1239.
[15]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.

细胞色素P450 1A1基因多态性对奥沙利铂联合卡培他滨方案治疗结直肠癌患者临床疗效的影响

Influence of CYP1A1 polymorphism on clinical outcomes of CRC patients treated by oxaliplatin plus capecitabine

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价